Scientists advance type 1 diabetes treatment with cutting-edge stem cell and gene editing technologies

Researchers review significant advancements and ongoing challenges in cell replacement therapies for type 1 diabetes, highlighting innovative approaches in stem cell-derived islets and immune protection strategies.

Azurity’s Nymalize solution in prefilled syringe gains FDA approval

Nymalize is indicated for use in adult patients with subarachnoid haemorrhage from ruptured intracranial berry aneurysms. Credit: Radiological imaging/Shutterstock. Azurity Pharmaceuticals’ Nymalize (nimodipine) oral solution

September 4, 2024

Cantourage Group SE records strong growth in revenue and EBITDA in the break-even range in 2023. Strong growth since the partial legalisation of cannabis came into force. – Biotech Investments

EQS-News: Cantourage Group SE / Key word(s): Annual Results/Quarter Results Cantourage Group SE records strong growth in revenue and EBITDA in the break-even range in

May 16, 2024

USC to lead $10.8 million study on hip fracture surgery options

The University of Southern California has been approved for $10.8 million in research funding by the Patient-Centered Outcomes Research Institute (PCORI) to compare approaches to

February 5, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.